Literature DB >> 23183788

Helicobacter pylori: tailored therapy with novel sequential quadruple therapies.

David Y Graham, Javier P Gisbert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23183788      PMCID： PMC3873761          DOI： 10.1038/nrgastro.2012.232

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

Review 1.  Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

Authors:  J P Gisbert; F Morena
Journal:  Aliment Pharmacol Ther       Date:  2006-01-01       Impact factor: 8.171

Review 2.  Optimal therapy for Helicobacter pylori infections.

Authors:  Emiko Rimbara; Lori A Fischbach; David Y Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

3.  Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies.

Authors:  L A Fischbach; S van Zanten; J Dickason
Journal:  Aliment Pharmacol Ther       Date:  2004-11-15       Impact factor: 8.171

4.  Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection.

Authors:  Alessandro Federico; Gerardo Nardone; Antonietta G Gravina; Maria Rosaria Iovene; Agnese Miranda; Debora Compare; Paola A Pilloni; Alba Rocco; Luigi Ricciardiello; Riccardo Marmo; Carmelina Loguercio; Marco Romano
Journal:  Gastroenterology       Date:  2012-04-03       Impact factor: 22.682

5.  Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.

Authors:  T J Borody; G Pang; A R Wettstein; R Clancy; K Herdman; R Surace; R Llorente; C Ng
Journal:  Aliment Pharmacol Ther       Date:  2006-02-15       Impact factor: 8.171

6.  Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.

Authors:  Ping-I Hsu; Deng-Chyang Wu; Jeng-Yih Wu; David Y Graham
Journal:  Helicobacter       Date:  2011-04       Impact factor: 5.753

7.  Efficacy of a modified sequential therapy including bismuth subcitrate as first-line therapy to eradicate Helicobacter pylori in a Turkish population.

Authors:  Ahmet Uygun; A Melih Ozel; Bulent Sivri; Zulfikar Polat; Halil Genç; Yusuf Serdar Sakin; Gürkan Çelebi; Oya Uygur-Bayramiçli; Cemal Nuri Erçin; Abdurrahman Kadayifçi; Ozdes Emer; Armagan Gunal; Sait Bagci
Journal:  Helicobacter       Date:  2012-08-26       Impact factor: 5.753

8.  Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations.

Authors:  C Y Tay; H M Windsor; F Thirriot; W Lu; C Conway; T T Perkins; B J Marshall
Journal:  Aliment Pharmacol Ther       Date:  2012-10-16       Impact factor: 8.171

9.  Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.

Authors:  Richard J Saad; Philip Schoenfeld; Hyungjin Myra Kim; William D Chey
Journal:  Am J Gastroenterol       Date:  2006-03       Impact factor: 10.864

10.  Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread.

Authors:  David Y Graham; Hong Lu
Journal:  Saudi J Gastroenterol       Date:  2012 Jan-Feb       Impact factor: 2.485
  10 in total
  2 in total

1.  Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence.

Authors:  David Y Graham; Yi-Chia Lee; Ming-Shiang Wu
Journal:  Clin Gastroenterol Hepatol       Date:  2013-06-08       Impact factor: 11.382

2.  Comparison of the efficacy and safety of hybrid and sequential therapies as a first-line regimen for Helicobacter pylori infection in Turkey.

Authors:  Ayşe Kefeli; Sebahat Başyigit; Abdullah Ozgur Yeniova; Serdar Ozkan; Yasar Nazligul
Journal:  Arch Med Sci       Date:  2016-03-16       Impact factor: 3.318
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.